captopril has been researched along with sorafenib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hye Khan, MA; Imig, JD; Nagasawa, T | 1 |
1 review(s) available for captopril and sorafenib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for captopril and sorafenib
| Article | Year |
|---|---|
Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib.
Topics: Acute Kidney Injury; Animals; Benzenesulfonates; Captopril; Growth Inhibitors; Hypertension; Male; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |